Exo-Exo DNA Polymerase Variants for Sequencing Accuracy

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing DNA polymerases with exonuclease activity can compromise sequencing accuracy by hydrolyzing incorporated modified nucleotides, and commercially available exonuclease-deficient mutants retain significant exonuclease activity, limiting their effectiveness in applications like sequencing by synthesis.

Innovation Solution

Development of exo−/exo− DNA polymerase variants with specific amino acid mutations that reduce exonuclease activity to negligible levels, ensuring minimal primer degradation and improved sequencing accuracy by maintaining high polymerase activity while eliminating exonuclease activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If exonuclease activity is present in DNA polymerase, then proofreading capability is improved, but modified nucleotides are hydrolyzed compromising incorporation regimen

Engineering Contradiction:
Improveproofreading capabilityVSAvoidhydrolysis of modified nucleotides
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The invention extracts and removes the exonuclease function from the DNA polymerase enzyme through site-directed mutagenesis of critical residues (D141A and E143A in Motif I). This creates an exonuclease-deficient polymerase that retains DNA synthesis capability while eliminating the harmful hydrolysis of modified nucleotides, thereby resolving the contradiction between proofreading capability and modified nucleotide stability.

Inventive Principle:
Principle #2Taking out (Extraction)

2Object-generated harmful factors

If exonuclease-deficient mutants are created, then modified nucleotide stability is improved, but residual exonuclease activity remains limiting effectiveness

Engineering Contradiction:
Improvemodified nucleotide stabilityVSAvoidsequencing accuracy
Core Design Contradiction:
Object-generated harmful factorsVSReliability

Solution Approach 1:

The invention applies parameter changes by mutating two critical aspartate residues (D141 and E143) in the exonuclease active site to alanine. This double mutation dramatically reduces exonuclease activity to negligible levels while preserving polymerase function, thereby eliminating residual exonuclease activity that limits sequencing effectiveness and improving both modified nucleotide stability and sequencing accuracy.

Inventive Principle:
Principle #35Parameter changes

3Productivity

If wild-type polymerase is used, then polymerase activity is maintained, but phasing errors occur due to primer degradation

Engineering Contradiction:
Improvepolymerase activityVSAvoidsequencing read quality
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The invention converts the potentially harmful exonuclease activity into a benefit by completely eliminating it through double mutation. This prevents primer degradation and phasing errors during sequencing, thereby improving sequencing read quality and accuracy while maintaining high polymerase activity for efficient DNA synthesis.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The exo−/exo− variants significantly reduce phasing errors, enhance sequencing read quality, and increase read length by minimizing primer degradation, resulting in higher fidelity and longer sequencing reads compared to wild-type enzymes.

Implementation Method 1

DNA polymerases catalyze DNA polymerization

Methodology Applied
Scientific EffectDNA polymerization: Chemical Bonding

Implementation Method 2

transfers the primer strand from the polymerase domain to the 3′-5′ exonuclease active site

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Data Source

PatentUS8921044B2DNA polymerase variants with reduced exonuclease activity and uses thereof
Publication Date: 2014.12.30 NEW ENGLAND BIOLABS INC
  • US8921044B2 patent drawing
  • US8921044B2 patent drawing
  • US8921044B2 patent drawing

AI summary

Compositions and methods are described to modify Family B DNA polymerases that contain residual exonuclease activity that interferes with sequencing techniques and with detection of single nucleotide polymorphisms. The compositions are mutant proteins with reduced exonuclease activity compared with presently available “exo−” polymerases, and a sensitive screening assay that enables an assessment of exonuclease activity of any synthetic DNA polymerase.